Here, based on a randomized pilot clinical trial, we report that intranasal oxytocin administration over an 8-week period led to effective reduction of obesity and reversal of related prediabetic changes in patients. This evidence concerns the gene OXT and obesity due to melanocortin 4 receptor deficiency.